

Authorized Claim Form No: C0019701792/2



On Behalf Of the Payer : Takaful Emarat Insurance PSC

Provider Name Peshawar Medical Centre
Date & Time 27-Jun-2023 03:27

User Name Ali Ahmed Ali
Fax No 2974343

Patient Information

Patient Name OLLI JERIAH USARAGA RYAN
Policy No. 01-115-01-23-8559787562
Policy Holder WINROSE PASULA USARAGA
Product Gold(D0%P0%C0%)

Date Of Birth 16-Apr-2019
Expiry Date 09-May-2024
Card No 4651-65A6-B57C-9265
National ID 784-2019-3440736-8
Identity Card 784-2019-3440736-8

Regulator Member ID I022-002-119371346-01

Medical Information

Consultation Date 27-Jun-2023
Hospitalization Motive Physical Illness
Physician Name Dr Ghodstehrani Mohammadmahdi
Length Of Stay 0.0
ER Triage 0

Family Of Benefits Out-Patient
Admission Date 27-Jun-2023
Physician Specialty Neonatology

Requested Services

Below Item (s) have been approved

Service Item	Description	Qty Claimed	Qty Approved	Remarks
10	Consultation Specialist	1.0	1.0	
94664	Demonstration and/or evaluation of patient utilization of an aerosol generator, nebulizer, metered dose inhaler or IPPB device	1.0	1.0	
96372	Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular	1.0	1.0	
0005-111805-1021	Chlorohistol (Chlorpheniramine [10 Mg/MI]) Solution For Injection (5 X 1ml, Ampoule)	0.2	0.2	
0006-124513-2071	Ventolin Nebules (Salbutamol [5 Mg/2.5ml]) Nebulizing Solution (20'S, Nebules)	1.0	1.0	
0125-122107-1022	Dexamethasone Sodium Phosphate (Dexamethasone [4 Mg/MI]) Solution For Injection (50 X 2ml, Ampoule)	0.02	0.02	
0188-135906-2441	Pulmicort (Budesonide [0.5 Mg/MI]) Suspension For Nebulization (2ml X 20, Unit)	0.25	0.25	
0195-107704-0802	Ceftriaxone-Tabuk (Ceftriaxone [1 G]) Powder For Injection (1 + 5ml, Vial + Solvent Ampoule)	1.0	1.0	

Estimated Cost (AED) : (203.93)

Authorization Notes

Authorization Form is valid until 27-Jul-2023

approved cons + 5/5 meds + admin charges as per agreed tariff

Disclaimer

1. NEXtCARE will only approve medical charges directly and strictly related to the case registered above. The final bill shall remain subject to billing rules, and to our auditing doctors' approval.
2. NEXtCARE hereby clearly reserves the right to decline any claim settlement due to misuse, abuse or tentative of fraud related either to the entry of the aforementioned information or to its trueness.
3. If you have any questions or require further information, please contact NEXtCARE Call Center on tel. no. 24 hours a day/7 days a week.
4. This form is subject to the terms, conditions, and procedures of the contract signed with NEXtCARE.